[{"data":1,"prerenderedAt":285},["ShallowReactive",2],{"compound-cjc-1295":3,"compound-related-cjc-1295":252,"compound-reading-cjc-1295":272},{"id":4,"title":5,"alsoKnownAs":6,"body":7,"casNumber":222,"category":223,"description":212,"extension":224,"faq":225,"meta":232,"molecularFormula":222,"molecularWeight":156,"name":5,"navigation":233,"path":234,"presentations":235,"purity":238,"rank":239,"relatedCompounds":240,"relatedResearch":244,"seo":248,"sequence":222,"stem":249,"summary":250,"__hash__":251},"compounds\u002Fcompounds\u002Fcjc-1295.md","CJC-1295","Modified GRF (1-29) · CJC-1295 without DAC",{"type":8,"value":9,"toc":211},"minimark",[10,15,19,22,89,92,96,99,106,112,115,119,173,177,180,183,187,194,197,201,204,208],[11,12,14],"h2",{"id":13},"what-cjc-1295-is","What CJC-1295 is",[16,17,18],"p",{},"CJC-1295 without DAC — more precisely, Modified GRF (1-29) — is a 29-amino-acid\nanalogue of growth hormone-releasing hormone. Native GHRH is a 44-residue\npeptide, but its receptor-activating activity resides in the first 29 residues,\nso GHRH (1-29) is the functional fragment that analogue development starts from.",[16,20,21],{},"Four substitutions distinguish the modified form from the native fragment:",[23,24,25,41],"table",{},[26,27,28],"thead",{},[29,30,31,35,38],"tr",{},[32,33,34],"th",{},"Position",[32,36,37],{},"Substitution",[32,39,40],{},"Purpose",[42,43,44,56,67,78],"tbody",{},[29,45,46,50,53],{},[47,48,49],"td",{},"2",[47,51,52],{},"D-Ala",[47,54,55],{},"Blocks DPP-4 cleavage, the primary degradation route",[29,57,58,61,64],{},[47,59,60],{},"8",[47,62,63],{},"Gln",[47,65,66],{},"Prevents asparagine deamidation during storage",[29,68,69,72,75],{},[47,70,71],{},"15",[47,73,74],{},"Ala",[47,76,77],{},"Improves bioactivity",[29,79,80,83,86],{},[47,81,82],{},"27",[47,84,85],{},"Leu",[47,87,88],{},"Prevents methionine oxidation",[16,90,91],{},"Two of the four are stability modifications aimed at the molecule sitting in a\nvial rather than at its behaviour in a receptor assay — asparagine deamidation\nand methionine oxidation are both classic degradation pathways in stored\npeptides.",[11,93,95],{"id":94},"with-and-without-dac","With and without DAC",[16,97,98],{},"The name CJC-1295 is used for two distinct molecules, and the distinction is\npharmacologically fundamental rather than cosmetic.",[16,100,101,105],{},[102,103,104],"strong",{},"Without DAC"," (Modified GRF 1-29, ~3,368 Da) has a short half-life and produces\na brief pulse of receptor activation resembling the endogenous pattern.",[16,107,108,111],{},[102,109,110],{},"With DAC"," (~3,647 Da) carries a maleimidoproprionic acid group that forms a\ncovalent bond with serum albumin, extending circulating half-life from minutes to\ndays and producing sustained rather than pulsatile receptor exposure.",[16,113,114],{},"That is not a subtle formulation difference — pulsatile versus continuous GHRH\nreceptor signalling is a well-recognised distinction in the endocrine\nliterature, and research designs generally depend on which one is being used.\nThe masses differ by roughly 280 Da, so mass spectrometry resolves the question\nunambiguously. This page describes the non-DAC form.",[11,116,118],{"id":117},"molecular-profile","Molecular profile",[23,120,121,131],{},[26,122,123],{},[29,124,125,128],{},[32,126,127],{},"Property",[32,129,130],{},"Value",[42,132,133,141,149,157,165],{},[29,134,135,138],{},[47,136,137],{},"Also known as",[47,139,140],{},"Modified GRF (1-29), CJC-1295 no-DAC",[29,142,143,146],{},[47,144,145],{},"Length",[47,147,148],{},"29 amino acids",[29,150,151,154],{},[47,152,153],{},"Molecular weight",[47,155,156],{},"~3,368 Da",[29,158,159,162],{},[47,160,161],{},"Receptor target",[47,163,164],{},"GHRH receptor",[29,166,167,170],{},[47,168,169],{},"Appearance",[47,171,172],{},"White lyophilised powder",[11,174,176],{"id":175},"research-context","Research context",[16,178,179],{},"CJC-1295 is used in growth hormone axis research as a GHRH receptor agonist —\nreceptor binding and selectivity work, cAMP accumulation as a functional readout\nin pituitary cell models, and comparative studies examining pulsatile versus\nsustained receptor stimulation. It appears frequently alongside growth hormone\nsecretagogue receptor agonists such as ipamorelin, since the two act on separate\nreceptors within the same axis.",[16,181,182],{},"Supplied for in-vitro laboratory research only. No therapeutic claim is made and\nno dosing or administration guidance is provided.",[11,184,186],{"id":185},"analytical-notes","Analytical notes",[16,188,189,190,193],{},"The with-DAC \u002F without-DAC ambiguity makes ",[102,191,192],{},"mass confirmation the load-bearing\ntest for this compound",". The two forms are close enough in behaviour on\nreversed-phase chromatography that a purity figure alone will not tell you which\nyou have, and far enough apart in mass that any real MS result will.",[16,195,196],{},"On the purity side, the substitutions at positions 8 and 27 exist specifically to\nclose off deamidation and oxidation pathways, which means that finding\ndeamidated or oxidised species in the impurity profile points at a manufacturing\nor storage failure rather than at an inherent property of the molecule. Those\nspecies elute close to the main peak, so the chromatogram matters more than the\nintegrated percentage.",[11,198,200],{"id":199},"handling-and-storage","Handling and storage",[16,202,203],{},"Store sealed at −20 °C, protected from light and moisture, and bring to room\ntemperature before opening. Reconstitute by running diluent down the vial wall\nand swirling. Store solution at 2–8 °C, protected from light, and avoid repeated\nfreeze-thaw.",[11,205,207],{"id":206},"what-we-supply","What we supply",[16,209,210],{},"Modified GRF (1-29) released against a ≥99% purity specification, with HPLC\npurity and mass spectrometry identity confirmation on every batch and a\nbatch-specific Certificate of Analysis on which the observed mass — and\ntherefore which form of the molecule you have — is stated explicitly. Select\nbatches additionally receive independent third-party purity verification.",{"title":212,"searchDepth":213,"depth":213,"links":214},"",2,[215,216,217,218,219,220,221],{"id":13,"depth":213,"text":14},{"id":94,"depth":213,"text":95},{"id":117,"depth":213,"text":118},{"id":175,"depth":213,"text":176},{"id":185,"depth":213,"text":186},{"id":199,"depth":213,"text":200},{"id":206,"depth":213,"text":207},null,"Growth Hormone","md",[226,229],{"question":227,"answer":228},"What is the difference between CJC-1295 with and without DAC?","DAC stands for Drug Affinity Complex — a maleimidoproprionic acid group that binds covalently to serum albumin and extends the circulating half-life from minutes to days. Without DAC, the compound is Modified GRF (1-29) and produces a short pulse. They are different molecules with different masses, and the certificate should make clear which one you have.",{"question":230,"answer":231},"What are the four modifications in Modified GRF (1-29)?","Four amino acid substitutions relative to native GHRH (1-29): D-Ala at position 2, which blocks DPP-4 cleavage; Gln at 8; Ala at 15; and Leu at 27. Together they improve enzymatic stability and manufacturing consistency without changing the receptor the molecule acts on.",{},true,"\u002Fcompounds\u002Fcjc-1295",[236,237],"2 mg vial","5 mg vial","≥99%",20,[241,242,243],"ipamorelin","cjc-1295-ipamorelin","tesamorelin",[245,246,247],"mass-spectrometry-peptide-identity","how-to-read-a-peptide-coa","net-peptide-content-vs-purity",{"title":5,"description":212},"compounds\u002Fcjc-1295","A modified growth hormone-releasing hormone analogue, engineered for resistance to enzymatic cleavage while retaining a short pulsatile signal.","ZfiQHTArBAbR3xTc4P6uhyMlFOY0b2rLQ2OOgFHCssg",[253,260,266],{"path":254,"name":255,"alsoKnownAs":256,"summary":257,"category":258,"molecularWeight":222,"purity":259},"\u002Fcompounds\u002Fcjc-1295-ipamorelin","CJC-1295 + Ipamorelin","GH axis blend","A combined preparation of Modified GRF (1-29) and ipamorelin, pairing a GHRH receptor agonist with a selective ghrelin receptor agonist.","Blends","≥99% per component",{"path":261,"name":262,"alsoKnownAs":263,"summary":264,"category":223,"molecularWeight":265,"purity":238},"\u002Fcompounds\u002Fipamorelin","Ipamorelin","NNC 26-0161","A selective growth hormone secretagogue receptor agonist, notable for acting on the ghrelin receptor without the appetite and cortisol effects of earlier secretagogues.","~711.9 Da",{"path":267,"name":268,"alsoKnownAs":269,"summary":270,"category":223,"molecularWeight":271,"purity":238},"\u002Fcompounds\u002Ftesamorelin","Tesamorelin","TH9507 · trans-3-hexenoyl-GHRH(1-44)","A stabilised analogue of full-length growth hormone-releasing hormone, distinguished by retaining all 44 residues rather than the 1-29 fragment.","~5,136 Da",[273,277,281],{"path":274,"title":275,"description":276},"\u002Fresearch\u002Fhow-to-read-a-peptide-coa","How to Read a Peptide Certificate of Analysis","A field-by-field walkthrough of a peptide COA — what each number establishes, which fields are load-bearing, and what a missing batch number tells you about the rest of the document.",{"path":278,"title":279,"description":280},"\u002Fresearch\u002Fmass-spectrometry-peptide-identity","What Mass Spectrometry Establishes That HPLC Cannot","Purity and identity are different questions requiring different instruments. Why a chromatogram alone cannot tell you which peptide is in the vial, and what a mass spectrum on a COA should actually show.",{"path":282,"title":283,"description":284},"\u002Fresearch\u002Fnet-peptide-content-vs-purity","Net Peptide Content vs Purity: The Two Numbers Everyone Confuses","A vial can be 99% pure and still contain 25% less peptide than the label says. Why purity and net peptide content are different measurements, and which one your concentration calculation actually needs.",1787473952836]